ArticleBMJ case reports2026
Paradoxical resolution of refractory subretinal fluid in dome-shaped macula after discontinuation of anti-VEGF therapy.
Article in BMJ case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic subretinal fluid (SRF) is a common complication of dome-shaped macula (DSM), yet its optimal management remains uncertain. This paper presents a case of spontaneous resolution of chronic SRF associated with DSM following discontinuation of anti-vascular endothelial growth factor (anti-VEGF) therapy. The patient, in her late 70s, with DSM and chronic SRF in the left eye was treated with multiple anti-VEGF agents, including ranibizumab, aflibercept and faricimab, over 19 months. Despite ongoing therapy, her SRF persisted and best-corrected visual acuity (BCVA) remained stable at 20/20 to 20/25. 45 days after treatment cessation, optical coherence tomography showed complete resolution of SRF. Over 26 months of subsequent observation without further treatment, the retina remained dry and BCVA remained stable. This suggests that in DSM, chronic SRF refractory to anti-VEGF therapy may spontaneously resolve after discontinuing treatment. Observation is a reasonable management strategy in specific patients to minimise unnecessary injections and associated risks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.